Zusammenfassung
Bereits der Name Botulinum Toxin A verrät viel über die Historie einer Substanz, die in den letzten Jahren eine sprunghafte Karriere vom Gift zum Arzneimittel erfahren hat. Bekannt geworden ist das Toxin als Verursacher des Botulismus, einer Lebensmittelvergiftung, die durch verdorbene Wurst- und Konservenwaren (Botulus lat. für Wurst) hervorgerufen wird. Im Jahr 1895 konnte das Bakterium Clostridium botulinum vom Mikrobiologen von Ermengem als Verursacher des Botulismus und Erzeuger des Botulinum Toxins identifiziert werden. Die wissenschaftliche Erstbeschreibung der Erkrankung geht 1817 auf den Arzt und Dichter Julius Kerner zurück, der erstaunlicherweise schon damals über einen therapeutischen Nutzen der Substanz spekulierte (Kerner 1817).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arens LJ, Leary PM, Goldschmidt RB (1997) Experience with botulinum toxin in the treatment of cerebral palsy. S Afr Med J 87:1001–1003.
Bandmann O, Marsden CD, Wood NW (1998) Atypical presentations of dopa-responsive dystonia. Adv Neurol 78:283–290.
Blasi J, Chapman E, Link E, Binz T, Yamasaki S, De Camilli P, Südhof T, Niemann H (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein. SNAP 25, Nature 365:160–163.
Boyd K, Patterson V (1989) Dopa responsive dystonia: a treatable condition misdiag¬nosed as cerebral palsy. BMJ, 298:1019–1020.
Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E (1994) Botulinum toxin A in management of cerebral palsy. Ped Neurol 10:284–288.
Chutorian AM, Root L (1994) Management of spasticity in children with Botulinum-A Toxin. International Pediatrics 9:35–43.
Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK (1997) Botulinum toxin A in the hémiplégie upper limb: a double-blind trial. Dev Med Child Neurol 39: 185–193.
Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 18:304–311.
Cosgrove AP, Corry IS, Graham HK (1994) Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36:386–396.
de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205.
Deuschl G (1994) Botulinumtoxin zur Behandlung Hyperkinetischer Störungen. Arzneimitteltherapie 8:235–237.
Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A (1999) The effect of botu¬linum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 41:226–232.
Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35:71–77.
Garcia RPJ, Sanchez BV, Urcelay V, San MV, Castillo F, Ferrer A, Campos J, Garcia de Y (1996) Botulinum A toxins in the treatment of spasticity in cerebral palsy during childhood. Neurologia 11:34–36.
Gooch JL, Sandell TV (1996) Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 77:508–511.
Greene P (1994) Controlled trials of botulinum toxin for cervical dystonia: a critical review. In: Jankowich J, Hallet M (eds) Therapy with Botulinum Toxin. Dekker, New York Basel Hong Kong, pp 279–287.
Haley SM, Coster WJ, Ruth MF (1991). A Content Validity Study of the Pediatric Evaluation of Disability Inventory. Pediatric Physical Therapy 177–184.
Hallett M (1999) One man’s poison—clinical applications of botulinum toxin. N Engl J Med 341:118–120.
Hambleton P, Moore P (1997) Botulinum Neurotoxins: Origin, Structure, Molecular Actions and Antibodies. In: Moore P (ed) Botulinum Toxin Treatment. Blackwell Science Ltd, Oxford, Cambridge, pp 16–27.
Heinen F, Mall V, Wissel J, Bernius P, Stücker R, Linder M, Philipsen A, Korinthenberg R (1997) Botulinum-Toxin A: Neue Möglichkeiten in der Behandlung spastischer Bewegungsstörungen. Monatsschrift Kinderheilkunde 145:1088–1092.
Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, Schenkel A, Stucker R, Korinthenberg R (1997) Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28:307–313.
Heinen F, Wissel J, Mall V, Philipsen A, Korinthenberg R (1998) Interventionelle Neuropädiatrie: Behandlungsmöglichkeiten mit Botulinum Toxin A. Aktuelle Neuropädiatrie 1997:251–259.
Heinen F, Linder M, Mall V, Kirschner J, Korinthenberg R (1999) Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A—the parents’ view of functional outcome. European Journal of Neurology 6 (Suppl 4):47–50.
Kerner J (1817) Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaft und Arzneikunde 3:1–25.
Koman LA, Mooney F, Smith B, Goodman A, Mulvaney T (1993) Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 13:489–495.
Koman LA, Mooney JF, Smith BP, Goodman A, Mulvaney T (1994) Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14:299–303.
Krageloh-Mann I, Hagberg G, Meisner C, Haas G, Eeg-Olofsson KE, Selbmann HK, Hagberg B, Michaelis R (1995) Bilateral spastic cerebral palsy—a collaborative study between southwest Germany and western Sweden. Ill: Aetiology. Dev Med Child Neurol 37:191–203.
Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R (1997) Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatric rehabilitation 1:235–237.
Mall V, Heinen F, Kirschner J, Linder M, Stein S, Michaelis U, Bernius P, Lane M, Korinthenberg R (2000) Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol 15 (4):214–217.
Massin M, Allington N (1999) Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 19:362–365.
Miller F, Bagg MR (1995) Age and migration percentage as risk factors for progression in spastic hip disease. Dev Med Child Neurol 37:449–455.
Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM (1994) Dopa-responsive 172 dystonia simulating cerebral palsy. Pediatr Neurol 11:236–240.
Palisano RJ (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73:651–658.
Pascual-Pascual SI, Sanchez de M, Roche MC, Pascual-Castroviejo I (1997) Botulinum toxin as a treatment for infantile cerebral palsy. Rev Neurol 25:1369–1375.
Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S (1989) The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 31:341–352.
Sackett DL (1986) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95 (Suppl 2):2–4.
Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12:924–927.
Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049.
Scrutton D, Rosenbaum P (1997) Locomotor development in children with cerebral palsy. In: Connolly KJ, Forssberg H (eds) Neurophysiology & neuropsychology of motor development, Vol 1. MacKeith Press, London, pp 101–123.
Sutherland D, Kaufman K, Wyatt M, Chambers H (1996) Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study.Gait & Posture 4:269–279.
Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait & Posture 10:1–9.
Tsui JK, Bhatt M, Calne S, Calne DB (1993) Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 43:183–185.
Wall S, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P (1993) Botulinum a chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 46:703–706.
Watanabe Y, Bakheit AM, McLellan DL (1998) A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil 20:62–65.
Wiegand H, Erdmann G, Wellhoner HH (1976) 1251-labelled botulinum a neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292 (2):161–165.
Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, Poewe W (1999) Botulinum Toxin A in the Management of Spastic Gait Disorders in Children and Young Adults with Cerebral Palsy: A Randomized, Double-Blind Study of “High-Dose” versus “Low-Dose” Treatment. Neuropediatrics 30:120–124.
Wissel J, Muller JJ, Heinen F, Mall V, Sojer M, Ebersbach G, Poewe W (1999) Safety and tolerance of single-dose botulinum toxin type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group. Wien Klin Wochenschr 111:837–842.
Wong V (1997) Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 18:124–131.
Zelnik N, Giladi N, Goikhman I, Keren G, Moris R, Honigman S (1997) The role of Botulinum Toxin in the Treatment of Lower Limb Spasticity in Children with Cerebral Palsy—A pilot study. Israel J Medical Sci 33:129–133.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mall, V., Herrmann, J., Berweck, S., Korinthenberg, R., Heinen, F. (2001). Botulinum Toxin A. In: Lohse-Busch, H., Riedel, M., Graf-Baumann, T. (eds) Das therapeutische Angebot für bewegungsgestörte Kinder. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59567-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-59567-7_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67917-2
Online ISBN: 978-3-642-59567-7
eBook Packages: Springer Book Archive